Portico Valve-in-Valve Retrospective Registry

Retrospective Assessment of the Portico Transcatheter Aortic Valve for Valve-in-Valve Use

The objective of this data-collection study is to retrospectively evaluate the safety and clinical performance of the Portico transthoracic aortic valve for Valve-in-Valve treatment of a failed aortic surgical bioprosthetic valve in patients who are considered at increased surgical risk for a redo surgical aortic valve replacement.

Study Overview

• Status: Completed
• Conditions: Aortic Stenosis; Aortic Valve Stenosis; Aortic Insufficiency; Aortic Valve Failure
• Intervention / Treatment: Device: Transcatheter Aortic Valve Replacement

Detailed Description

Two options currently exist to treat failed surgical aortic bioprostheses: transcatheter valve-in-valve implantation (ViV) or redo surgical aortic valve replacement (rAVR). The objective of this comprehensive data-collection study is to retrospectively evaluate the safety and clinical performance of the Portico transthoracic aortic valve for Valve-in-Valve treatment of a failed aortic surgical bioprosthetic valve in patients who are considered at increased surgical risk for a redo surgical aortic valve replacement.

• Study Type: Observational
• Enrollment (Actual): 71

Contacts and Locations

• Study Contact: Name: Karine Miquel, PhD; Phone Number: +32479600107; Email: karine.miquel@abbott.com
• Study Contact Backup: Name: Nels Engblom; Phone Number: (319) 853-3946; Email: nels.engblom1@abbott.com

Study Locations

• Australia
  • Adelaide, Australia
    • GenesisCare - St Andrew's Hospital & GenesisCare Leabrook - Satellite Site of GenesisCare - Wesley Hospital
  • Auchenflower, Australia, QLD 4066
    • GenesisCare - Wesley Hospital
• Denmark
  • Copenhagen, Denmark
    • Rigshospitalet
• Germany
  • Bad Nauheim, Germany
    • Kerckhoff-Klinik gGmbH
  • Rostock, Germany
    • Universitätsklinikum Rostock (AöR)
• United Kingdom
  • London, United Kingdom, EC1A 7BE
    • St. Bartholomew's Hospital
  • Morriston, United Kingdom
    • Morriston Hospital - ABM University Health Board

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Study may enroll up to 100 patients who had a documented failed surgical aortic bioprosthetic valve (due stenosis, insufficiency, or a combination of both) at increased risk for redo surgical aortic valve replacement surgery. Patients must have met the sizing requirements of the Portico transthoracic aortic valve sizing specification (≥19 mm and ≤27 mm). Patients must meet all inclusion and exclusion criteria to be eligible for enrollment.

In addition, an exploratory registry arm will collect data for patients that were treated for a failed surgical bioprosthetic aortic valve true inner diameter size of <19 mm or >27 mm. There will be no enrollment limit in the exploratory registry arm

Description

Inclusion Criteria:

1. Subject had a degenerated surgical aortic bioprosthetic valve with severe aortic stenosis, severe regurgitation, or a combination of at least moderate stenosis with at least moderate regurgitation per EAPCI-ESC-EACTS standardized criteria.
2. Surgical bioprosthesis true inner diameter (true ID) was ≥ 19 mm and ≤ 27 mm and was confirmed by either CT or confirmed by the Valve in Valve Aortic App. Refer to the PCR website https://www.pcronline.com/PCR-Publications/PCR-mobile-apps/Valve-in-Valve-Aortic-app Note: if CT was contraindicated and/or not possible to be obtained, a transesophageal echocardiogram (TEE) will be accepted for sizing.
3. Prior to Portico ViV procedure, the patient was deemed at increased risk for surgery to replace the surgical aortic bioprosthetic valve.
4. Subject provided written informed consent prior to performing data collection for study specific visits. For patients that are deceased at the time of enrollment, all institutional/local legal and regulatory requirements for consent must be met prior to enrollment and data collection.
5. Subject is ≥ 18 years of age or legal age in host country at the time of consent.
6. Prior to the Portico ViV index procedure, the subject had New York Heart Association (NYHA) class II, III, or IV.
7. Subject had a minimum vessel diameter of 6.0 mm for Portico™ delivery system access or a minimum of 5.0 mm for the FlexNav™ delivery system.
8. Subject had the Portico or FlexNav delivery system enter their vasculature

Exclusion Criteria:

1. Subject had evidence of an acute MI, percutaneous intervention, or a peripheral intervention ≤30 days prior to Portico ViV index procedure (MI defined as: ST Segment Elevation as evidenced on 12 Lead ECG).
2. Subject had uncontrolled blood dyscrasias defined as: leukopenia (WBC<3,000 mm3), acute anemia (Hb <9 g/dL), or thrombocytopenia (platelet count <50,000 cells/mm³).
3. Subject was considered hemodynamically unstable at the time of the ViV procedure (requiring inotropic support or mechanical heart assistance)
4. Subject had severe ventricular dysfunction with left ventricular ejection fraction (LVEF) <20% as measured by resting echocardiogram.
5. Subject had imaging evidence of intracardiac mass, thrombus or vegetation.
6. Subject had an active peptic ulcer or has/had upper gastrointestinal (GI) bleeding ≤3 months prior to ViV index procedure.
7. Subject had a documented history of a cerebrovascular accident (CVA) or a transient ischemic attack (TIA) ≤6 months prior to index procedure.
8. Subject had renal insufficiency (serum creatinine >3.0 mg/dL (265.5μmol/L)) and/or end stage renal disease requiring chronic dialysis.
9. Subject had active bacterial endocarditis or ongoing sepsis ≤ 6 months prior to the index procedure.
10. Surgical aortic bioprosthetic valve was unstable or rocking.
11. Subject had a vascular condition (i.e. stenosis, tortuosity, or severe calcification) that made insertion and endovascular access to the aortic valve impossible.
12. Subject was unable to tolerate antiplatelet or anticoagulant therapy

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Primary Analysis Population; The primary analysis population will include patients who have signed an Informed Consent Form, and at minimum, the Portico delivery system entered his/her vasculature for an attempted Portico ViV implant. Patients must have met the sizing requirements of the PorticoTM transthoracic aortic valve sizing specification (≥19 mm and ≤27 mm).	Device: Transcatheter Aortic Valve Replacement; Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
Exploratory Registry Arm; The exploratory registry arm will collect data for patients that were treated for a failed surgical bioprosthetic aortic valve true inner diameter size of <19 mm or >27 mm.	Device: Transcatheter Aortic Valve Replacement; Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The rate of all-cause mortality, disabling stroke, life-threatening bleeding requiring blood transfusion, acute kidney injury (AKI) requiring dialysis, and major vascular complication adverse events at 30-days post-procedure.	Composite of all-cause mortality, disabling stroke, life threatening bleeding requiring blood transfusion, acute kidney injury (AKI) requiring dialysis, and major vascular complications	30 days post index procedure
The rate of all-cause mortality and disabling stroke adverse events at 1-year post-procedure.	Composite of all-cause mortality or disabling stroke	1 year post index procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Procedure Success (descriptive endpoint)	Defined as absence of procedural mortality AND successful access, delivery of the valve, and retrieval of the delivery system	Procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), Transient Ischemic Attacks (TIA), Myocardial infarction (MI), New pacemaker implant (PPI), Coronary obstruction, Minor, Major, and life-threatening bleeding, major vascular, access-related, or cardiac structure complication, acute kidney injury (AKI) stages 1-4	30 days post index procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), Transient Ischemic Attacks (TIA), Myocardial infarction (MI), New pacemaker implant (PPI), Coronary obstruction	1 year post index procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), TIA	2 years post index procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), TIA	3 years post index procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), TIA	4 years post index procedure
Evaluation of adverse event rates (descriptive endpoint)	All-cause mortality, Cardiovascular-related mortality, All Stroke (by severity), TIA	5 years post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	30 days post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	1 year post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	2 years post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	3 years post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	4 years post index procedure
Clinical Benefit Endpoint	Change in New York Heart Association (NYHA) functional classification from baseline to 30 days, 1 year, and annually through 5 years	5 years post index procedure

Collaborators and Investigators

• Sponsor: Abbott Medical Devices
• Investigators: Study Director: Vinny Podichetty, Abbott

Study record dates

Study Major Dates

• Study Start (Actual): October 21, 2021
• Primary Completion (Actual): December 29, 2023
• Study Completion (Actual): December 29, 2023

Study Registration Dates

• First Submitted: July 27, 2021
• First Submitted That Met QC Criteria: August 4, 2021
• First Posted (Actual): August 12, 2021

Study Record Updates

• Last Update Posted (Actual): February 9, 2024
• Last Update Submitted That Met QC Criteria: February 7, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Pathological Conditions, Anatomical; Aortic Valve Disease; Heart Valve Diseases; Ventricular Outflow Obstruction; Aortic Valve Stenosis; Aortic Valve Insufficiency; Constriction, Pathologic
• Other Study ID Numbers: ABBOTT-CIP-10414

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes